Lupin Strengthens LATAM Footprint with Biosimilar Ranibizumab Deal

has entered into a strategic licensing and supply agreement with SteinCares to commercialise its biosimilar Ranibizumab across Latin America (excluding Mexico and Argentina). Under this collaboration, Lupin will handle manufacturing, while SteinCares will lead regulatory approvals and distribution. Ranibizumab, widely used to treat retinal diseases like age-related macular degeneration and diabetic macular edema, marks a key addition to SteinCares’ biosimilar portfolio and reinforces Lupin’s commitment to expanding affordable eye care solutions globally. This move positions Lupin to tap into the growing demand for advanced yet cost-effective biologics in the LATAM market, strengthening its international biosimilar presence. Follow me for more such posts, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.